Skip to main content

Table 3 Association of pre-chemotherapy cell counts and pre-chemotherapy frailty

From: The longitudinal relationship between immune cell profiles and frailty in patients with breast cancer receiving chemotherapy

Pre-chemotherapy Pre-chemotherapy frailty score β (SE)  
Neutrophils 0.041**      
(0.018)      
Lymphocytes   0.043     
  (0.051)     
Monocytes    0.069    
   (0.090)    
NLR     0.044***   
    (0.017)   
LMR      0.001  
     (0.002)  
WBC       0.037**
      (0.015)
Age 50–64 − 0.134 − 0.132 − 0.147 − 0.132 − 0.134 − 0.151
(0.109) (0.109) (0.109) (0.111) (0.111) (0.104)
Age 65+ − 0.298* − 0.289* − 0.281* − 0.276* − 0.275* − 0.270*
(0.153) (0.154) (0.153) (0.156) (0.155) (0.146)
White (yes = 1) − 0.272* − 0.261 − 0.230 − 0.313* − 0.273 − 0.256*
(0.162) (0.162) (0.160) (0.165) (0.167) (0.153)
Married (yes = 1) − 0.261** − 0.245** − 0.250** − 0.283** − 0.280** − 0.248**
(0.113) (0.114) (0.113) (0.115) (0.115) (0.109)
Some college or above = 1 − 0.271** − 0.226* − 0.233** − 0.259** − 0.220* − 0.268**
(0.116) (0.116) (0.116) (0.118) (0.118) (0.110)
Constant 1.846*** 1.902*** 1.929*** 1.955*** 2.006*** 1.730***
(0.210) (0.228) (0.201) (0.203) (0.200) (0.221)
Observations 513 516 517 499 495 553
R-squared 0.043 0.032 0.031 0.047 0.033 0.044
  1. Linear regression models were used to evaluate the association between cell counts and frailty, controlling for age (below 50, 50–64 versus ≥ 65 years), race (Caucasian versus others), marital status (married versus others), and education (≥ some college versus ≤ high school)
  2. NLR neutrophil to lymphocyte ratio, LMR lymphocyte to nonocyte ratio
  3. *Significant at 10%; **significant at 5%; ***significant at 1%